Compile Data Set for Download or QSAR
Report error Found 288 Enz. Inhib. hit(s) with all data for entry = 9387
TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404137((2S,5R)-1-(2,2'-dimethoxy-[1,1'-biphenyl]-4-carbon...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404138((2S,5R)-1-(2-fluoro-2'-methoxy-[1,1'-biphenyl]-4-c...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404134((2S,5R)-5-(2-chlorophenyl)-1-(2',5'-dimethoxy-[1,1...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404133((2S,5R)-5-(2-chlorophenyl)-1-(3',5'-dimethoxy-[1,1...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404124((2S,5R)-5-(2-chlorophenyl)-1-(3',4'-dimethoxy-[1,1...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404122((2S,5R)-5-(2-chlorophenyl)-1-(2',3'-dimethoxy-[1,1...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404110((2S,5R)-5-(2-chlorophenyl)-1-(4-(6-methoxy-2-methy...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404156((2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-4-(6-metho...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404152((2S,5R)-1-(3-chloro-4-(2,4-dimethoxypyrimidin-5-yl...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404144((2S,5R)-5-(2-chlorophenyl)-1-(4-(2,6-dimethylpyrid...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404139((2S,5R)-5-(2-chlorophenyl)-1-(2-fluoro-2'-methoxy-...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404181((2S,5R)-5-(2-chlorophenyl)-1-(4-(4,6-dimethoxypyri...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404182((2S,5R)-5-(2-chlorophenyl)-1-(4-(3,6-dimethoxypyri...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404179((2S,5R)-5-(2-chlorophenyl)-1-(5'-cyano-2'-methoxy-...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404180((2S,5R)-5-(2-chlorophenyl)-1-(5'-cyano-2'-methyl-[...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404177((2S,5R)-5-(2-chlorophenyl)-1-(2'-methyl-3'-(methyl...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404176((2S,5R)-1-(3'-amino-2'-methyl-[1,1'-biphenyl]-4-ca...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404174((2S,5R)-5-(2-chlorophenyl)-1-(3'-cyano-2'-methoxy-...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404170((2S,5R)-5-(2-chlorophenyl)-1-(4-(2,4-dimethoxypyri...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404171((2S,5R)-5-(2-bromophenyl)-1-(2'-methoxy-[1,1'-biph...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404196((2S,5R)-5-(2-chlorophenyl)-1-(2'-cyano-4',5'-dimet...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404197((2S,5R)-5-(2-chlorophenyl)-1-(3',4',5'-trimethoxy-...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404195((2S,5R)-5-(2-chlorophenyl)-1-(5'-cyano-2',3'-dimet...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404192((2S,5R)-1-(4'-amino-2'-methoxy-[1,1'-biphenyl]-4-c...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404190((2S,5R)-5-(2,4-difluorophenyl)-1-(4-(2,6-dimethoxy...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404191((2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-4-(5-metho...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404189((2S,5R)-5-(2-fluorophenyl)-1-(2'-methoxy-4'-(methy...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404185((2S,5R)-1-(4'-acetamido-2'-methoxy-[1,1'-biphenyl]...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404184((2S,5R)-5-(2-chlorophenyl)-1-(2'-methoxy-4'-(methy...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404214((2S,5R)-5-(2-chlorophenyl)-1-(2-fluoro-3'-(methyls...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404215((2S,5R)-5-(2-chlorophenyl)-1-(2'-cyano-2-fluoro-[1...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM408723(US10358416, Compound 387 | (2S,5R)-5-(2-chlorophe...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404213((2S,5R)-5-(2-chlorophenyl)-1-(2-fluoro-4'-(methyls...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404206((2S,5R)-1-(5'-cyano-2'-methoxy-[1,1'-biphenyl]-4-c...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404207((2S,5R)-1-(4-(2,6-dimethoxypyridin-3-yl)-3-fluorob...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404202((2S,5R)-5-(2-chlorophenyl)-1-(4-(2,6-dimethoxypyri...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404203((2S,5R)-5-(2-chlorophenyl)-1-(3-fluoro-4-(6-methox...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404201((2S,5R)-5-(2-chlorophenyl)-1-(2-fluoro-3',4'-dimet...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403786((2S,5R)-5-(2-chlorophenyl)-1-(3-methoxy-5-phenetho...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404237((2S,5R)-5-(2-chlorophenyl)-1-(2'-cyano-4'-(trifluo...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403767((2S,5R)-5-(2-chlorophenyl)-1-(2'-fluoro-[1,1'-biph...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403773((2S,5R)-5-(2-chlorophenyl)-1-(4'-methyl-[1,1'-biph...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404236((2S,5R)-1-(2'-chloro-5'-cyano-[1,1'-biphenyl]-4-ca...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403763((2S,5R)-5-(2-chlorophenyl)-1-(2'-methyl-[1,1'-biph...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403764((2S,5R)-1-(3-((4-chlorobenzyl)oxy)-5-methoxybenzoy...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM403752((2S,5R)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-bip...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404231((2S,5R)-1-(2'-cyano-4'-methoxy-[1,1'-biphenyl]-4-c...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404228((2S,5R)-5-(2,3-difluorophenyl)-1-(2'-methoxy-[1,1'...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404229((2S,5R)-5-(2,5-difluorophenyl)-1-(2'-methoxy-[1,1'...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

TargetFree fatty acid receptor 2(Human)
Epics Therapeutics

US Patent
LigandPNGBDBM404253((2S,5R)-5-(2,3-difluorophenyl)-1-(4-(2,4-dimethoxy...)
Affinity DataEC50: <200nMAssay Description:The assay was used to determine the activity of the compounds of the invention.The [35S]GTPγS assay was incubated in 20 mM HEPES pH7.4, 100 mM N...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/2/2021
Entry Details
US Patent

Displayed 1 to 50 (of 288 total ) | Next | Last >>
Jump to: